Recombinant Human Erythropoeitin (Alfa Epo) is now widely available and widely used to maintain haemoglobin between 10-11 g/dL. It is given three times per week at the end of haemodialysis session or as subcutaneous injection for those with Chronic Renal Failure (no renal replacement therapy) or those on Continuous Ambulatory Peritoneal Dialysis (CAPD). Complications: hypertension … Continue reading Erythropoeitin – EPO